The prevalence and clinical features of pulmonary embolism in patients with AE-COPD: A meta-analysis and systematic review

Fu, Xiaofang; Zhong, Yueyang; Xu, Wucheng; Ju, Jiangang; Yu, Min; Ge, Minjie; Gu, Xiaofei; Chen, Qingqing; Sun, Yibo; Huang, Huaqiong; Shen, Linfeng

doi:10.1371/journal.pone.0256480

Cited by 21 publications

(11 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a meta-analysis comprising 3170 patients admitted for acute exacerbation of COPD, there was a high prevalence of PE and DVT in this clinical profile (pooled prevalence, 17.2% [95% CI, 13.4%–21.3%] and 7.1% [95% CI, 3.7%–11.4%], respectively). 8…”

Section: Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary E...mentioning

confidence: 99%

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

Tsao¹,

Aday²,

Almarzooq³

et al. 2023

Circulation

3,560

702

View full text Add to dashboard Cite

BACKGROUND: The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health. The Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, congenital heart disease, rhythm disorders, subclinical atherosclerosis, coronary heart disease, heart failure, valvular disease, venous disease, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs). METHODS: The American Heart Association, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing. The 2023 Statistical Update is the product of a full year’s worth of effort in 2022 by dedicated volunteer clinicians and scientists, committed government professionals, and American Heart Association staff members. The American Heart Association strives to further understand and help heal health problems inflicted by structural racism, a public health crisis that can significantly damage physical and mental health and perpetuate disparities in access to health care, education, income, housing, and several other factors vital to healthy lives. This year’s edition includes additional COVID-19 (coronavirus disease 2019) publications, as well as data on the monitoring and benefits of cardiovascular health in the population, with an enhanced focus on health equity across several key domains. RESULTS: Each of the chapters in the Statistical Update focuses on a different topic related to heart disease and stroke statistics. CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.

show abstract

Section: Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary E...mentioning

confidence: 99%

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

Tsao¹,

Aday²,

Almarzooq³

et al. 2023

Circulation

3,560

702

View full text Add to dashboard Cite

show abstract

“…Thus, the above-mentioned factors may lead to a varied amount of literature that meets the requirements in a similar search period. Recently published meta-analyses of AECOPD combined with PE reported a prevalence of 17.2 and 12.9%, respectively ( 48 , 49 ). We included 20 studies involving 5,854 people, higher than those included in the two recently published papers.…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, they have little information about the related symptoms, signs, and risk factors ( 68 ). Recently, Fu et al also reported the clinical features of AECOPD combined with VTE ( 48 ). Furthermore, following anticoagulant therapy, there was no significant difference in the risk of recurrent VTE, compared with those without COPD ( 69 ).…”

Section: Discussionmentioning

confidence: 99%

“…Data in our study were only acquired from partly countries in WHO regions; therefore, we could not obtain data from other countries. Fu et al also conducted a subgroup analysis on the regions; however, the results were different owing to different included studies and regional divisions (48). The incidence and prevalence of VTE and COPD differ among different regions and races (54)(55)(56).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Pulmonary Embolism and Deep Venous Thromboembolism in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Han

Wang

Xie

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundAcute exacerbation of chronic obstructive pulmonary disease (AECOPD) increases the risk of pulmonary embolism (PE) and deep venous thrombosis (DVT). AECOPD combined with PE and DVT poses challenges for treatment and management. This necessitates prevention and management to estimate the overall prevalence of PE and DVT among patients with AECOPD and to identify the risk factors.MethodsWe searched the PubMed, Embase, and Cochrane Library databases from their inception to January 9, 2021 and extracted the data from the included studies. The risk of bias was assessed for each study. We separately calculated the prevalence of PE and DVT in patients with AECOPD. Subgroup analysis and meta-regression analyses were performed to determine the sources of heterogeneity. Furthermore, we assessed the publication bias.ResultsThe meta-analysis included 20 studies involving 5,854 people. The overall prevalence of PE and DVT among patients with AECOPD was 11% (95% CI: 0.06–0.17) and 9% (95% CI: 0.06–0.12), respectively. Subgroup analysis demonstrated that the prevalence of PE among patients with AECOPD was 12, 2, 7, and 16% in the European, South-East Asia, Western Pacific, and Eastern Mediterranean regions, respectively, and the DVT was 10, 9, 9, and 4%, respectively. The prevalence of PE among patients with AECOPD aged ≥ 70 and <70 years old was 6 and 15%, respectively, and the DVT was 8 and 9%, respectively. The prevalence of PE among patients with AECOPD diagnosed within 48 h and other times (beyond 48 h or not mentioned) was 16 and 6%, respectively, and DVT was 10 and 7%, respectively.ConclusionThe pooled prevalence of PE and DVT among patients with AECOPD was insignificantly different between the different age groups and the WHO regions. However, the early diagnosis was associated with a higher prevalence of PE. Clinicians and the public need to further improve the awareness of prevention and management for PE and DVT among patients with AECOPD.Systematic Review RegistrationPROSPERO, identifier CRD42021260827.

show abstract

“…A meta-analysis involving 3,170 AECOPD patients showed that the prevalence of PTE and DVT in AE-COPD patients was 17.2% and 7.1%, respectively. 21 However, the link between fibrinogen and DVT/PTE is unclear, since Watz et al found that fibrinogen was inversely associated with levels of physical activity, 14 and the lack of physical exertion is itself a risk factor of the development of DVT/PTE. AECOPD patients tend to have reduced physical exercise due to respiratory dysfunction and/or muscle weakness, which could partly contribute to higher levels of fibrinogen.…”

Section: Discussionmentioning

confidence: 99%

Fibrinogen, a Promising Marker to Evaluate Severity and Prognosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Observational Study

Sun¹,

Cao²,

Ma³

et al. 2022

COPD

View full text Add to dashboard Cite

Background Fibrinogen is increasingly being studied as an inflammatory biomarker in chronic obstructive pulmonary disease (COPD), but there are limited data on the role of fibrinogen in assessing the severity of acute exacerbation of COPD (AECOPD). This study aimed to explore whether circulating fibrinogen could be used as a surrogate to measure the severity and predict the prognosis of AECOPD. Methods A total of 535 AECOPD patients diagnosed at our center from January 2016 to June 2021 were retrospectively enrolled in this study. The electronic medical record of each patient was retrieved to collect data on baseline characteristics and laboratory parameters, as well as the use of noninvasive positive-pressure ventilation (NPPV) and prognosis. Multiple linear regression analysis was used to identify independent factors associated with circulating fibrinogen values. Receiver-operating characteristic curve and multivariate logistic regression analysis were applied to further verify the use of fibrinogen to predict NPPV failure. Results Compared to patients with fibrinogen <4 g/L, patients with increased fibrinogen levels (>4 g/L) tended to have elevated inflammatory response and higher incidence of DVT/PTE, emphysema, pneumonia, and atherosclerosis. In addition, fibrinogen levels in NPPV-failure patients were significantly higher than non-NPPV patients and NPPV-success ones. The presence of emphysema, pneumonia, and history of long-term oxygen therapy and higher CRP levels and leukocyte counts were independent risk factors associated with increased fibrinogen levels in AECOPD. Furthermore, our data indicated that fibrinogen could be considered as a reliable biomarker to predict NPPV failure (AUC, 0.899, 95% CI 0.846–0.952), with an OR of 7.702 (95% CI 2.984–19.875; P <0.001). Conclusion The level of circulating fibrinogen can be used to measure severity of AECOPD, and among AECOPD patients managed with NPPV, fibrinogen >3.55 g/L can independently predict NPPV failure.

show abstract

The prevalence and clinical features of pulmonary embolism in patients with AE-COPD: A meta-analysis and systematic review

Cited by 21 publications

References 57 publications

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

Prevalence of Pulmonary Embolism and Deep Venous Thromboembolism in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Fibrinogen, a Promising Marker to Evaluate Severity and Prognosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Observational Study

Contact Info

Product

Resources

About